Abstract 72P
Background
The working space in the submucosal tunnel of endoscopic submucosal tunnel technique (ESTT) is limited, and the visual field is obscure during close inspection or hemostasis. This retrospective study aimed to evaluate the efficacy and safety of a novel near-focus mode technique for accurate operation during the submucosal tunneling endoscopic procedure.
Methods
A retrospective two-center study was designed. A total of 51 patients undergoing ESTT procedures with near-focus mode (n = 29) or traditional mode (n = 22) between February 2016 and May 2019 were included in this study. Data regarding the efficacy, complications, hospital stay period, and other parameters were recorded.
Results
When using the near-focus mode during the ESTT procedure, it is convenient to acquire a clear image and accurate operation. The clinical success rate was 100% (29/29) in near-focus group, higher than that in traditional group (90.9%, 20/22), although the difference was not significant (P = 0.181). The adverse event occurred more frequently in traditional group (45.5%) compared to that in the near-focus group (17.2%, P = 0.036). Especially, the near-focus group exhibited a significantly lower rate of bleeding compared to that of the traditional group (0 vs 18.2%, P = 0.029). Furthermore, the mean hospital stay after procedure was shorter in near-focus group (5.7 days) than that in traditional group (6.7 days, P = 0.013).
Conclusions
The visual field is more clearly exposed within submucosal tunneling by using near-focus mode than traditional procedures. The efficacy and safety of this novel technique was proved in our procedures.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
Xiangsheng Fu.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
465P - A phase IIIb open-label study of afatinib in EGFR TKI-naïve patients (pts) with EGFR mutation-positive (EGFRm+) NSCLC: Exploratory biomarker analysis
Presenter: Jie Wang
Session: Poster display session
Resources:
Abstract
470P - Prognostic significance of serum biomarkers in small cell lung cancer: A meta-analysis and systematic review
Presenter: Rogelio Velasco
Session: Poster display session
Resources:
Abstract
471P - Chemotherapy in advanced thymic malignancies
Presenter: Ankur Varshney
Session: Poster display session
Resources:
Abstract
466P - Cancer immunotherapy efficacy and patients’ age: A systematic review and meta-analysis
Presenter: Yu Jiang
Session: Poster display session
Resources:
Abstract
506P - Efficacy and safety of pegvorhyaluronidase alfa (PEGPH20; PVHA) and pembrolizumab (pembro) combination therapy in patients (Pts) with stage III/IV non-small cell lung cancer (NSCLC)
Presenter: Jeffrey Ward
Session: Poster display session
Resources:
Abstract
480P - Safety and efficacy of dacomitinib for EGFR+ NSCLC in the subgroup of Asian patients from ARCHER 1050
Presenter: Tony S.K. Mok
Session: Poster display session
Resources:
Abstract
503P - Activity of afatinib in patients (pts) with NSCLC harboring uncommon EGFR mutations: Pooled analysis of three large phase IIIB trials
Presenter: Antonio Passaro
Session: Poster display session
Resources:
Abstract
488P - Randomized trial of prophylactic minocycline for erlotinib-associated skin rash in non-small cell lung cancer (PEARL trial)
Presenter: Kei Kusaka
Session: Poster display session
Resources:
Abstract
495P - Tracking of activating EGFR mutations predicts progression-free survival in advanced EGFR-mutated NSCLC patients treated with osimertinib
Presenter: Anna Buder
Session: Poster display session
Resources:
Abstract
520P - A phase II study to evaluate abscopal effect by palliative radiation therapy in nivolumab treatment for pretreated non-small cell lung cancer (HANSHIN 0116)
Presenter: Akito Hata
Session: Poster display session
Resources:
Abstract